Regeneron has been busy, with two health tech deals announced this week: One is about genetic data and one about AI. Both of them are about developing and selling drugs, really.

Regeneron Pharmaceuticals is set to acquire substantially all assets of 23andMe for $256 million. The deal is expected to close in Q3 2025

Viz.ai's recent partnership with Sanofi and Regeneron Pharmaceuticals (NasdaqGS:REGN) brings AI technology to aid in the management of COPD patients, enhancing the healthcare process. Throughout the past month,

Regeneron Pharmaceuticals will acquire embattled DNA testing company 23andMe in a $256 million court-supervised sale, promising to honor existing privacy protections and continue consumer services with no changes.

On May 15, 2025, a jury returned a verdict finding Amgen Inc. (“Amgen”) liable for antitrust violations and awarding Regeneron Pharmaceuticals,

All participants will initially undergo a run-in period on standardised medium-dose ICS/LABA to confirm persistent lack of control before randomisation.

Viz.ai, the leader in AI-powered disease detection and intelligent care coordination, today announced a multi-year partnership with Sanofi (NASDAQ: SNY), an innovative global healthcare company, and Regeneron (NASDAQ: REGN),